Pfizer (PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results. The study met its primary endpoint, with tilrekimig showing a ...
Study met primary endpoint, demonstrating statistically significant increase in the percentage of participants achieving EASI-75 at Week 16 across all doses tested, compared to placebo Tilrekimig ...
Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs. The Big Pharma evaluated three ...
Please provide your email address to receive an email when new articles are posted on . CLEVELAND — For patients with atopic dermatitis, today’s systemic therapies can lead to long-standing on-drug ...
In this video from the American Academy of Dermatology Annual Meeting, Lawrence F. Eichenfield, MD, discusses new treatment ...
Pfizer said a Phase 2 study of tilrekimig met its key goals in adults with moderate to severe atopic dermatitis, the most common form of eczema, and that it plans to accelerate the drug candidate into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results